Search clinical trials for: Group 2 ustekinumab 130 mg

Total 4303 results

Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Australia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Belgium, Hungary, Croatia, ...
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Serbia, South Africa, Japan, Israel, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Austria, Ireland, Czech Republic, Hungary, Denmark, Icela...
Janssen-Cilag Ltd.

Completed

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease (POWER)

Crohn Disease

United States, Korea, Republic of, Netherlands, France, Austria, Italy, United Kingdom, Germany, Russian Federation, Spain, Czechia, Sweden
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis

Nonradiographic Axial Spondylitis, Ankylosing

Australia, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Argentina, Mexico, Poland, Korea, Republic of, Russian Federation, Hungary, Czechia
Janssen Research & Development, LLC

Completed

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

Primary Biliary Cirrhosis

United States, Canada
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Russian Federation, Austria, Hungary, ... and more
Janssen Research & Development, LLC

Completed

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age (CADMUS Jr)

Psoriasis

United States, Germany, Taiwan, Belgium, Korea, Republic of, Canada, Poland, Hungary, Netherlands
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Centocor, Inc.

Completed

A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Taiwan, Korea, Republic of
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis

Psoriasis

Japan
Janssen Research & Development, LLC

Withdrawn

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

China
Janssen Research & Development, LLC

Terminated

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Japan, Korea, Republic of, Canada, Taiwan, Thailand, Germany, China, Serbia, Spain, Portugal, Russian Federation, Poland, Ukraine, Lithuania, South Africa, Hungary, Argentina, Bulgaria, Colombia
Janssen Pharmaceutical K.K.

Terminated

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Dermatomyositis | Polymyositis

Japan
Bausch Health Americas, Inc.

Terminated

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

Plaque Psoriasis

United States, Belgium, Italy, Hungary, Poland, Australia, France, Greece, Russian Federation, Latvia, Canada
Janssen Biotech, Inc.

Completed

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis (PSTELLAR)

Psoriasis

United States
Centocor, Inc.

Completed

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

Crohn's Disease

United States, France, United Kingdom, Germany, Spain, Belgium, Israel, Australia, Canada, Netherlands, New Zealand, Austria
Centocor, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease

Crohn Disease

United States, Canada, Belgium
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
Janssen Research & Development, LLC

Completed

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

Arthritis, Psoriatic

United States, France, Poland, United Kingdom, Germany, Canada, Sweden, Russian Federation, Austria, Hungary
Janssen Research & Development, LLC

Completed

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

Arthritis, Psoriatic

United States, Australia, Poland, United Kingdom, Germany, Spain, Canada, Finland, New Zealand, Russian Federation, Austria, Hungary, Lithuania, Latvia
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Completed

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

Study of Belimumab Administered Subcutaneously to Healthy Subjects

Healthy

United States
Janssen Scientific Affairs, LLC

Completed

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year (SEAVUE)

Crohn Disease

United States, Belgium, Korea, Republic of, Netherlands, Italy, United Kingdom, Canada, France, Australia, Bulgaria, Poland, Germany, Serbia, Czechia, Russian Federation, Spain, Brazil, Hungary
Taiwan Liposome Company

Completed

Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients

Osteoarthritis of the Knee

Taiwan, Australia
Natrogen Therapeutics International, Inc

Unknown

Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis

Ulcerative Colitis

United States
MediBeacon

Completed

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

Acute Kidney Injury

United States
Oxford Cannabinoid Technologies Holdings PLC
Simbec-Orion Group

Completed

Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers

Healthy

United Kingdom
Grünenthal GmbH

Completed

A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

Acute Pain

France
Warner Chilcott

Completed

Treatment of Erectile Dysfunction - Long Term Safety and Efficacy

Erectile Dysfunction

United States
Rigel Pharmaceuticals

No longer available

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

Immune Thrombocytopenic Purpura
Hawthorne Effect Inc.
Uqora, Inc.

Terminated

Uqora Supplements in Women With UTIs

Urinary Tract Infections

United States
UroGen Pharma Ltd.

Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Bladder Cancer

Israel
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Ukraine, Taiwan, Poland, Korea, Republic of, Russian Federation, Czechia
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Canada, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Portugal, Bulgaria, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia
LG Life Sciences

Completed

Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg

Hypertension | Hyperlipidemia

Korea, Republic of
HighField Biopharmaceuticals Corporation
Tigermed Consulting Co., Ltd

Recruiting

Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

Solid Tumor, Adult

China
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
Janssen Research & Development, LLC

Completed

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

Arthritis, Rheumatoid

Poland, Ukraine, Colombia, Bulgaria, United States, Singapore, Russian Federation, Argentina, Hungary, Chile, Czech Republic
Bayer

Completed

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Neoplasm

United States
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

IGA Nephropathy

United States, United Kingdom, Hong Kong, Taiwan, Austria, Germany
CicloMed LLC
Cmed Clinical Services

Completed

Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Janssen Research & Development, LLC

Completed

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

Healthy

China
Warner Chilcott

Completed

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

Postmenopausal Osteoporosis

United States
Johns Hopkins All Children's Hospital

Terminated

Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

Central Nervous System Tumors

United States
Novartis Pharmaceuticals

Completed

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Chronic Plaque Type Psoriasis

Germany, United States, Belgium, Korea, Republic of, Spain, Taiwan, Australia, Austria, Italy, Estonia, Israel, Bulgaria, Netherlands, France, Switzerland, Portugal, Slovakia, Norway, United Kingdom, Hungary, Turkey, Canada, Denmark, ...
Sprout Pharmaceuticals, Inc

Terminated

12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress

Depression | Sexual Dysfunctions, Psychological

United States
Impax Laboratories, LLC

Completed

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
AbbVie
Boehringer Ingelheim

Completed

BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

Search clinical trials for: Group 2 ustekinumab 130 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations